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Abstract 
Aims 
To determine the specific role of podocyte-expressed cannabinoid-1 receptor (CB1R) in the 
development of diabetic nephropathy (DN), relative to CB1R in other renal cell types. 
Material and methods 
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We developed a mouse model with a podocyte-specific deletion of CB1R (pCB1Rko) and 
challenged this model with streptozotocin (STZ)-induced type-1 DN. We also assessed the 
podocyte response to high glucose in vitro and its effects on CB1R activation. 
Results 
High glucose exposure for 48h led to an increase in CB1R gene expression (CNR1) and 
endocannabinoid production in cultured human podocytes. This was associated with podocyte 
injury reflected by decreased podocin and nephrin expression. These changes could be prevented 
by Cnr1-silencing, thus identifying CB1R as a key player in podocyte injury. After 12 weeks of 
chronic hyperglycemia, STZ-treated pCB1Rko mice showed similar elevated blood glucose as 
their wild-type littermates. However, they displayed less albuminuria and less podocyte loss than 
STZ-treated wild-type mice. Unexpectedly, pCB1Rko mice also have milder tubular dysfunction, 
fibrosis and reduction of cortical microcirculation compared to wild-type controls, which is partly 
mediated by podocyte-derived endocannabinoids acting via CB1R on proximal tubular cells.  
Conclusions 
Activation of CB1R in podocytes contributes to both glomerular and tubular dysfunction in type-
1 DN, which highlights the therapeutic potential of peripheral CB1R blockade. 
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Introduction 
Diabetes mellitus (hereafter referred to as diabetes) has reached pandemic proportions with an 
estimated 415 million individuals suffering from diabetes worldwide in 2015, which is projected 
to increase to 642 million by 2040. DN, is a leading cause of chronic kidney disease (CKD) and 
end-stage renal disease and contributes to excess morbidity and mortality. DN is a microvascular 
complication of both type-1 and type-2 diabetes (T1D, T2D) and characterized by dysfunction and 
injury to the glomerular filtration barrier, leading to albuminuria. Chronic injury leads to 
glomerulosclerosis, interstitial fibrosis and tubular atrophy, which manifests clinically as a 
reduction in glomerular filtration rate [1, 2]. 
Podocytes are highly specialized epithelial cells that wrap around the glomerular tuft in 
juxtaposition to the glomerular basement membranes thereby covering the glomerular capillaries. 
Podocyte foot processes form slits that represent one layer of the glomerular filtration barrier and 
enable the efficient ultrafiltration of blood to form tubular fluid [3]. The structural integrity of 
podocytes is key for proper glomerular function and podocyte injury underlies the progression of 
several renal pathologies [4]. Additionally, podocytes interact with mesangial and glomerular 
endothelial cells through various paracrine mediators to maintain normal glomerular functions and 
disruption in this cellular cross-talk may contribute to DN [5, 6]. 
The endocannabinoid system (ECS) is mainly comprised of 2 membrane receptors (CB1R 
and CB2R) and their 2 major endogenous ligands, N-arachidonoyl-ethanolamine (anandamide or 
AEA) and 2-arachidonoyl-glycerol (2-AG). In addition to its well-documented role in obesity and 
its metabolic complications [7], the ECS has been implicated in the pathogenesis of CKD including 
DN [8, 9]. Both CB1R and CB2R are expressed in the human and rodent kidney [8], particularly in 
mesangial cells [10], podocytes [11], and proximal tubular cells [12, 13]. Enzymes responsible for 
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the biosynthesis and degradation of endocannabinoids are also expressed in the kidney [9, 14]. We 
have previously reported that CB1R activation in podocytes mediates podocyte injury caused by 
hyperglycemia and increased RAAS activity in a rat model of T2D [11]. Furthermore, in vitro 
exposure of podocytes to high glucose increases CB1R expression, and this effect is abrogated by 
CB1R blockade [15]. However, the specific role of CB1R in podocytes in the development of DN, 
relative to CB1R in other renal cell types remains unclear. Here we report that podocyte-specific 
genetic deletion of CB1R partially protects against the streptozotocin-induced glomerular 
dysfunction and, surprisingly, also prevents proximal tubular injury, possibly by improving the 
renal microcirculation and also by preventing the release of humoral factors involved in tubular 
damage from podocytes. These observations highlight the key pathogenic role of podocyte CB1R 
in DN. 
 
RESULTS 
High-glucose activates the ECS in podocytes and promotes podocyte injury. 
Chronic exposure of human cultured podocytes to high-glucose (30 mM) elicited a significant 
increase in CNR1 but not CNR2 expression within 48h, as compared to cells exposed to 5 mM 
glucose. This was accompanied by an increase in the cellular levels of AEA and 2-AG (Figure 
1A). High-glucose exposure also decreased gene expression of podocin (NPHS2) and nephrin 
(NPHS1), proteins involved in maintaining podocyte integrity, while increasing gene expression 
of desmin (DES), a protein marker of podocyte injury, after 48h and 72h (Figure 1B). Furthermore, 
48h exposure to 30 mM glucose increased podocyte-secretion of pro-inflammatory cytokines, 
including Chemokine Ligand-2 (CCL2, also called monocyte chemoattractant protein-1; MCP-1), 
tumor necrosis factor-α (TNF-α), and interleukin-18 (IL-18) (Figure 1C). Furthermore, gene 
expression of transforming growth factor β1 (TGFB1) was similarly strongly increased (Figure 
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1D). To determine if these changes were related to CB1R activation, we exposed podocytes to 30 
mM high-glucose for 48h in the presence of CNR1-siRNA. Treatment with CNR1-siRNA 
completely abolished the high-glucose-induced CNR1 overexpression, reducing CNR1 mRNA 
significantly below that of cells maintained in normal glucose, without influencing CNR2 
expression (Figure 1E). In addition, CNR1 knock-down completely prevented the high-glucose-
induced podocyte injury, as indicated by the normalization of podocin (NPHS2), nephrin (NPHS1) 
and desmin (DES) gene expression (Figure 1F). The high-glucose-mediated secretion of CCL2, 
TNF-α, IL-18, and TGFB1 expression were also significantly attenuated by CNR1 knockdown 
(Figure 1E, 1G). To establish whether these observations were relevant in vivo, we developed a 
mouse model with a podocyte-specific deletion of Cnr1. 
 
Podocyte-specific deletion of Cnr1 mitigates the loss of glomerular function in streptozotocin-
treated diabetic mice. 
Deletion of Cnr1 in podocytes was first assessed by cell-specific genotyping. Podocytes-nuclei 
stained for the marker Wilms’ tumor-1 (WT-1) were laser captured using the xMD method. 
Compared to wild-type podocytes, pCB1Rko podocytes showed a shift in the DNA band for Cnr1 
in WT-1+ but not WT-1- nuclei (Supplementary figure 1A), indicating podocyte-specific deletion 
of Cnr1. The absence of CB1R protein in podocytes was confirmed by co-localization with 
podocalyxin as visualized by double immuno-fluorescence/confocal microscopy (Supplementary 
figure 1B). The phenotype of pCB1Rko mice was indistinguishable from that of their wild-type 
Cre+ littermates, displaying comparable body and kidney weights and normal parameters of kidney 
function. They also had similar endocannabinoids levels, but half as much CB1R mRNA in the 
renal cortex compared to wild-type littermates (Figure 2). Twelve weeks after STZ-treatment to 
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induce hyperglycemia, body weight of the two strains remained similar, but wild-type mice had 
higher kidney weight (Figure 2A) and higher Cnr1 expression in renal cortices as compared to 
diabetic pCB1Rko mice (Figure 2B). Meanwhile, cortical levels of AEA and 2-AG remained 
similar in the two strains (Figure 2C). 
Wild-type and pCB1Rko mice developed similar STZ-induced hyperglycemia and a 
similar increase in hA1c (Figure 2D). However, after 12 weeks of chronic hyperglycemia, 
pCB1Rko mice displayed significantly lower levels of blood urea nitrogen (BUN) and less 
albuminuria compared to their STZ-treated wild-type littermates (Figure 2E), suggesting better 
preserved glomerular and podocyte functions in the former. Correspondingly, pCB1Rko mice were 
protected from podocyte loss, as demonstrated by significant preservation of WT-1 and 
podocalyxin immunostaining (Figure 2F). In addition, diabetic wild-type mice displayed an 
increase in glomerular tuft area, which remained normal in diabetic pCB1Rko mice (Figure 2F). 
These histological observations were consistent with altered gene expression profiles. Indeed, the 
diabetes-induced decrease in the expression of genes encoding for structural podocyte proteins 
such as Nphs2, Nphs1 and zonula occludens (Tjp1) was absent in diabetic pCB1Rko mice (Figure 
2G). Interestingly, the diabetes-induced increased expression of Des, which correlates with 
podocyte injury, was not influenced by the deletion of CB1R in podocytes (Figure 2G). Structural 
analysis by electron microscopy revealed mild segmental/variable thickening of glomerular 
basement membranes (GBM) with foot process fusion in the STZ-treated wild-type mice and 
focally shorter foot processes. In contrast, podocyte foot processes and GBMs were comparable 
between the citrate- and STZ-treated pCB1Rko mice although minor irregularities could be 
appreciated in the GBM thickness of STZ-treated pCB1Rko mice (Supplementary figure 2). 
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Podocyte-specific deletion of Cnr1 partially prevents proximal tubular cell injury and loss of 
function. 
In addition to its protective effect on podocyte function, podocyte-specific deletion of Cnr1 also 
protected some tubular cell functions. For instance, pCB1Rko mice had lower urine output, less 
glycosuria and urinary N-acetylglucosamine (NAG) activity, and increased expression of the 
proximal tubular cell marker megalin (Lrp2) in renal cortices compared to their wild-type 
littermates (Figure 3A). Interestingly, diabetic wild-type and pCB1Rko mice displayed similar 
increases in the expression of the sodium/glucose cotransporter 2 (SGLT2, Slc5a2) protein despite 
different levels of glycosuria (Figure 3A). Again, no differences in gene expression were observed 
under non-diabetic conditions except for a small increase in Lrp2 expression in pCB1Rko 
compared to wild-type mice. 
Alterations in arginine metabolism, as reflected by increased expression of Arg2, results in 
vascular dysfunction in diabetes which contributes to the pathogenesis of DN [16]. We observed 
a strong increase in arginase-2 protein in renal cortices from diabetic mice compared to non-
diabetic wild-type mice, whereas no such increase was detectable in diabetic pCB1Rko mice 
(Figure 3B). Furthermore, lipocalin 2 has been linked to tubular cells apoptosis and renal lesion 
[17], and its protein and gene expression was strongly increased by diabetes in wild-type mice and 
much less so in pCB1Rko mice (Figure 3B). Renal cortical fibrosis was evident in diabetic wild-
type but not pCB1Rko mice, as documented histologically by Picro-Sirius Red staining and by 
corresponding changes in the gene expression of pro-fibrotic markers Col1a, Timp1, Tgfb1 and 
Fn1 (Figure 3B). Furthermore, the commonly observed hyperglycemia-induced increase in 
caspase 3/7 activity was also attenuated in diabetic pCB1Rko compared to diabetic wild-type mice 
(Figure 3C). 
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Absence of CB1R in podocytes prevents the diabetes-induced increase in oxidative stress and 
inflammation in renal cortices. 
In wild-type mice, diabetes was associated with increased ROS production in renal cortices, and 
corresponding increases in the expression of ROS-generating NADPH oxidase isoforms, such as 
NADPH oxidase4 (Nox4), p47phox and Nox1. On the other hand, no such diabetes-induced 
changes were detected in pCB1Rko mice (Figure 4A). Additionally, a strong infiltration of 
macrophages was evident in the glomeruli and interstitial space between proximal tubule cells of 
diabetic wild-type but not in pCB1Rko mice, as indicated by the ionized calcium binding adaptor 
molecule (Iba-1, microglia/macrophage-specific calcium binding protein) staining and by the 
parallel changes in the gene expression of macrophage markers Cd68 and F4/80 (Figure 4B). This 
macrophage infiltration, in turn, was associated with an increase in the gene expression of the pro-
inflammatory markers Ccl2, Tnf, Il6 and Il18 but not Il1b (Figure 4C). 
 
Absence of CB1R in podocytes mitigates diabetes-induced hypoxia and decrease in renal 
microcirculation. 
Microvascular density has been suggested as a component of CKD progression and as such may 
be impacted in diabetes [18, 19] and resulting in chronic hypoxia [20]. Because the genetic deletion 
of CB1R in podocytes had a protective effect on both glomerular and tubular functions, we 
explored the possibility of a parallel improvement in renal microcirculation, as assessed by Laser 
speckle contrast analysis (LASCA) [21, 22] and illustrated in Supplementary figure 3 where 
changes in blood flow are evident during renal ischemia/reperfusion. Under normal conditions, 
wild-type and pCB1Rko mice had similar levels of renal microcirculatory flux. However, diabetes 
in wild-type mice resulted in decreased renal microcirculation, while no such decrease was evident 
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in pCB1Rko mice (Figure 4D). Additionally, in renal cortices from diabetic wild-type mice, the 
gene and protein expression of hypoxia-inducible factor-α (Hif1a) was increased and that of 
vascular endothelial growth factor-A (Vegfa) reduced relative to control wild-type mice (Figure 
4E). Furthermore, diabetic renal cortices displayed increased gene expression of the angiogenic 
factor thrombospondin-1 (Thsb1) and of the HIF-1α target, NADH dehydrogenase-1α subcomplex 
4-like2 (Ndufa4l2) [23], as well as an increase in the lactate-to-pyruvate ratio, a marker of tissue 
hypoxia, relative to non-diabetic controls (Figure 4F). These diabetes-related changes were absent 
or attenuated in diabetic pCB1Rko mice, suggesting that podocyte CB1R activity plays a critical 
role in mediating the decrease in renal cortical blood flow, and thus, the resulting tissue hypoxia. 
 
Podocyte-derived factors regulate proximal tubular cell function 
To further explore the possible involvement of podocyte-derived factors in damaging tubular cell 
function, we prepared conditioned medium (CM) from podocytes exposed to high glucose for 48h. 
This CM was then supplemented with either vehicle (DMSO) or CB1R antagonist JD5037 and 
used to incubate renal proximal tubular cells (RPTC) for an additional 48h in parallel with RPTC 
incubated in normal (5mM) or high glucose (30mM) media. Both high glucose and CM induced 
CNR1 expression in RPTC while the presence of JD5037 completely prevented this effect (Figure 
5A). While high glucose alone could reduce megalin (LRP2) and increase lipocalin 2 (LCN2), 
vimentin (VIM-1) and arginase 2 (ARG2) expression suggesting RPTC impairment, podocyte-CM 
significantly exacerbated these effects, suggesting the involvement of podocyte-derived factors in 
promoting tubular dysfunction (Figure 5B). Remarkably, CB1R antagonism prevented the CM-
induced additional damage regarding LRP2, LCN2 and ARG2 expression, while fully blocking the 
increase in VIM-1 (Figure 5B). Interestingly, the minimal effects of high glucose on RPTC’s 
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CCL2, TNF, IL18 and TGFB expression were significantly increased by exposure to podocyte-
CM, particularly for CCL2 expression, which was dramatically increased (Figure 5C). The 
potentiation of the effects of high glucose by podocyte-CM was fully or partially abrogated in the 
presence of JD5037 (Figure 5C). 
 
DISCUSSION 
Podocytes are essential components of the glomerular ultrafiltration apparatus, and their injury has 
been well established as a key pathogenic factor in the proteinuria and glomerulopathy associated 
with various forms of CKD, including DN. Recent evidence highlighted the role of 
endocannabinoids acting via CB1R in both type-1 DN [24] and type-2 DN [11, 25], although the 
specific role of CB1R in podocytes has remained unclear. Here we generated a podocyte-specific 
CB1R knockout mouse strain to determine whether activation of CB1R in podocytes significantly 
contributes to impaired glomerular functions, including albuminuria, in type-1 DN induced in mice 
by STZ treatment. Unexpectedly, we also found that activation of podocyte CB1R induces tubular 
dysfunction, fibrosis and the reduction of renal cortical microcirculation in STZ-induced DN. 
Lastly, we demonstrate that soluble factors released by podocytes in response to CB1R activation 
may mediate a crosstalk between podocytes and proximal tubular epithelial cells.     
An upregulation of renal CB1R has been linked to the development of DN [10, 11, 24, 25] 
and renal fibrosis [26]. In turn, CB1R antagonists have been identified as potential therapeutic 
tools, as the globally active CB1R antagonist rimonabant ameliorates albuminuria and reduces 
glomerular and tubular damage in rodent models of obesity/diabetes [15, 25] and also reduces 
albuminuria in STZ-treated mice with type-1 DN [24]. Although the clinical use of rimonabant is 
precluded by its CNS-mediated side effects, peripherally restricted CB1R antagonism is devoid of 
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such undesired effects while still effective in maintaining and restoring podocyte integrity and 
functions in a rat model of type-2 DN [11]. However, the cellular localization of CB1R responsible 
for these effects is not clear, as gluco- and/or lipotoxic stress increases CB1R expression not only 
in podocytes [15], but also in renal cortical mesangial cells [10] and proximal tubular cells [13, 27, 
28], and CB1R activation leads to the apoptosis of both cell types [10, 28].  
In order to investigate the specific role of podocyte CB1R in DN, we developed the first 
podocyte-specific CB1R knock-out mouse model. Podocyte-specific deletion of CB1R mitigated 
albuminuria and the increase in BUN in STZ-treated mice without affecting their hyperglycemia, 
indicating improved glomerular functions and better preserved podocyte integrity. Furthermore, 
STZ-induced tubular dysfunction, as indicated by polyuria, glycosuria, and decreased cortical 
expression of megalin, was also mitigated by the absence of CB1R in podocytes, suggesting that 
podocyte injury may influence tubular epithelial cell health and function in a CB1R-dependent 
manner. 
One possible explanation for this unexpected finding is that an improvement of glomerular 
filtration and reduction in albuminuria and other filtered tubulotoxins directly leads to decreased 
proximal tubulointerstitial damage [29-31]. We have found that the absence of CB1R from 
podocytes mitigated the hyperglycemia-induced lipocalin 2 overexpression in tubular cells, which 
may also be related to the decrease in albuminuria in diabetic pCB1Rko mice, as it was previously 
shown that an increase in albumin promotes tubular cell death by inducing Ca2+-dependent 
endoplasmic reticulum stress, leading to lipocalin 2 overexpression [17]. Similarly, an increase in 
albumin can induce TNF-α, CCL2 and platelet-derived growth factor secretion by tubular cells, 
and these cytokines can serve as a trigger for the development of interstitial fibrosis [32, 33].   This 
deleterious effect of albuminuria can be facilitated by the high glucose-mediated increase in 
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metalloproteinase activity in tubular cells that leads to the shedding of the megalin/cubilin 
complex, which contributes to the impaired tubular clearance of filtered proteins including albumin 
[34, 35], as they are partially reabsorbed via megalin [36]. The tubular expression of megalin is 
reduced during obesity or diabetes and is restored by pharmacological inhibition of CB1R [11, 37], 
as demonstrated in the present study.  
Another explanation involves a paracrine interaction between podocytes and renal 
proximal tubular cells (RPTC). Injured podocytes are known to release various cytokines including 
TNF-α, VEGFA, TGF-β and IL-6 [38-40] which, in turn, may reach tubular cells and influence 
their activity. We have found that podocytes can release endocannabinoids when injured by 
exposure to high glucose or angiotensin II [11], and the released endocannabinoids could similarly 
act on neighboring cells, including RPTC. Indeed, RPTC express CB1R [37], which is upregulated 
in streptozotocin-induced type-1 diabetes [27] and its activation promotes RPTC hypertrophy [41], 
an early sign of DN. Furthermore, a recent report demonstrated a critical role for RPTC-expressed 
CB1R in the context of obesity-induced nephropathy [13] where it mediates RPTC inflammation 
and fibrosis. Here we demonstrated that incubating RPTC in conditioned medium from high 
glucose-exposed podocytes prompts an overexpression of the RPTC proteins involved in tubular 
damage, including TNF-α, CCL2, vimentin-1, lipocalin 2 and arginase 2. In parallel, a decrease in 
megalin expression suggests tubular dysfunction. Moreover, these changes significantly exceeded 
those induced by high glucose alone, and were partially or completely abrogated in the presence 
of 100 nM JD5037. This provides strong evidence for a previously unrecognized paracrine 
function of podocyte-derived endocannabinoids acting on CB1R of RPTC, inducing and 
aggravating tubular damage. However, we cannot exclude the possibility that factors released by 
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podocytes might stimulate RPTC’s to produce endocannabinoids, whose autocrine actions are then 
blocked by the CB1R antagonist. 
In addition, a CB1R-mediated increase in TGF-β production by podocytes facilitates the 
synthesis of pro-fibrogenic proteins such as type IV collagen, fibronectin or metalloproteinase 
inhibitors [42]. Thus, podocyte-CB1R contributes to the induction of interstitial fibrosis and tubular 
atrophy [43]. Diabetic glomerular fibrosis involves the accumulation of extracellular matrix 
proteins in the mesangial interstitial space, resulting in either diffuse or nodular changes [44], and 
podocyte damage or loss leads to glomerulosclerosis [45]. CB1R exerts pro-fibrogenic action in 
various tissues [46, 47], including kidneys, where its genetic invalidation or pharmacological 
blockade markedly reduced renal fibrosis in mice with unilateral ureteral ligation [26], in which 
CB1R blockade reduced renal fibrosis by inhibiting macrophage infiltration by reducing CCL2 
synthesis [26]. Similarly, pharmacological blockade of CB1R using rimonabant abolished the high 
glucose-mediated increase in profibrogenic genes in cultured podocytes [15]. These results agree 
with the profibrogenic role of podocyte CB1R and their additional involvement in the associated 
macrophage infiltration in both glomeruli and the interstitial space around tubular cells, which 
maintains a pro-inflammatory environment.  
 Contrary to our findings, Barutta et al reported that the overexpression of the pro-fibrotic 
proteins, TGF-β, fibronectin, and connective tissue growth factor in the cortex were unaltered by 
the CB1R antagonist rimonabant in STZ-treated mice [24]. However, in a more recent study using 
the same model, they found significant suppression of pro-fibrogenic gene and protein expression 
by the peripherally restricted neutral CB1R antagonist AM6545 [48]. Furthermore, in db/db mice 
with type-2 DN, CB1R blockade with rimonabant decreased albuminuria and suppressed the 
cortical expression of profibrotic (TGF-β1, type IV collagen, PAI-1) and pro-inflammatory 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
markers (CCL2) [15]. Together, these findings support the pro-fibrogenic role of CB1R in the 
kidney. 
Primary glomerular disease disrupts blood flow into the interstitium due to changes in 
vascular tone. Such microvascular changes appear prior to the decline in kidney function in STZ-
treated rats [18]. Moreover, interstitial fibrosis and extracellular matrix accumulation impair 
oxygen diffusion to tubular and interstitial cells by increasing the distance between blood vessels 
and nearby cells [49], leading to tissue hypoxia. Our observations of diabetic wild-type kidney are 
compatible with advance stage renal cortical hypoxia, as evidenced by reduced cortical 
microcirculation, reduced Vegfa expression likely resulting from endothelial cell apoptosis [50], 
increased Hif1a, thbs1, ndufa4/2 gene expression and increased lactate-to-pyruvate ratio, which 
are all markers of tissue hypoxia. Strikingly, the absence of podocyte CB1R mitigated all of these 
diabetes-induced changes, suggesting a critical role of podocyte CB1R in the control of vascular 
endothelial function and ultimately cortical microcirculation.  Such an effect may be mediated 
indirectly, through the pro-fibrogenic influence of podocyte CB1R that promotes tissue hypoxia. 
Additionally, activation of podocyte CB1R may result in the release of humoral factors that may 
have a paracrine damaging action on vascular endothelial cells. Although we have not tested such 
a cell-to-cell communication between podocytes and endothelial cells, podocytes- or endothelial 
cells-derived endocannabinoids may be involved, given our experimental results with conditioned 
media. The involvement of endocannabinoids is further suggested by published evidence that 
CB1R agonists suppress, while CB1R inhibitors increase, Vegf expression in a 
proinflammatory/fibrogenic environment [51, 52].  
 In conclusion, we have shown that podocyte CB1R play a key role in the impaired 
glomerular functions, proximal tubulopathy, interstitial fibrosis, and reduced microcirculation 
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associated with DN. Importantly, tubular dysfunction may be mediated, in part, by the paracrine 
or autocrine action of endocannabinoids acting via CB1R on proximal tubular cells as 
schematically illustrated in Figure 5D.     
 
METHODS 
For a detailed description of materials and methods used, see supplementary methods. 
 
Animals and induction of diabetes 
All animal protocols conformed to the National Institutes of Health (NIH) guidelines and were 
approved by the Institutional Animal Care and Use Committee of the National Institute on Alcohol 
Abuse and Alcoholism.  
 
Renal microcirculation  
Renal microcirculation was assessed by Laser speckle contrast analysis (LASCA) using the 
moorFLPI-2 blood flow imager (Moor Instruments, Wilmington, DE, USA).  
 
Statistics  
Values are expressed as means ± SEM. Data were analyzed by ANOVA followed by the Tukey-
Kramer post-hoc test. Time-dependent variables were analyzed and results in multiple groups were 
compared by ANOVA followed by the Bonferroni test. (GraphPad Prism version 7 for Windows, 
San Diego, CA). Significance was set at P<0.05. 
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Figure 1: High-glucose mediated effects on endocannabinoid tone, podocyte health and 
inflammatory status of human podocytes.  
A) CNR1 and CNR2 gene expression, anandamide (AEA), 2-arachidonoyl glycerol (2-AG) and 
arachidonic acid in podocytes exposed to either 5 (white bars) or 30 mM (black bars) glucose for 
24-48-72h. B) Podocin (NPHS2), nephrin (NPHS1) and desmin (DES) gene expression in 
podocytes exposed to either 5 (white bars) or 30 mM (black bars) glucose for 24-48-72h. C-D) 
Chemokine ligand 2 (CCL2), tumor necrosis factor-α (TNF-α), interleukin-18 (IL-18) protein 
secretion and transforming growth factor β1 (TGFB1) gene expression in podocytes exposed to 
either 5 (white bars) or 30 mM (black bars) glucose for 24-48-72h. E) CNR1 and CNR2 gene 
expression in human podocytes exposed to 5 (white bars) or 30 mM glucose for 48h in presence 
of control-siRNA (Ctrl, black bars) or CNR1-siRNA (grey bars). F) Podocin (NPHS2), nephrin 
(NPHS1) and desmin (DES) gene expression in podocytes exposed to 5 (white bars) or 30 mM 
glucose for 48h in presence of control-siRNA (Ctrl, black bars) or CNRl-siRNA (grey bars). G) 
Chemokine ligand 2 (CCL2), tumor necrosis factor α (TNF-α), interleukin-18 (IL-18) protein 
secretion and transforming growth factor β1 (TGFB1) gene expression in podocytes exposed to 5 
(white bars) or 30 mM glucose for 48h in presence of control-siRNA (Ctrl, black bars) or CNR1-
siRNA (grey bars). Columns and bars represent means ± SEM from 2 independent experiments 
with 6 replicates each. Significant differences from values in 5 mM glucose *P<0.05, **P<0.01, 
*** P<0.001 or Ctrl-siRNA treated cells #P<0.05, ##P<0.01, ### P<0.001. 
 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
 
 
 
 
 
 
 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
Figure 2: Effect of the streptozotocin-mediated hyperglycemia on ECS activity and 
glomerular function of pCB1Rko mice. 
A) Body and kidney weight along with kidney/body weight ratio. B) Cnr1 gene expression in renal 
cortices. C) Anandamide (AEA), 2-arachidonoyl glycerol (2-AG) content of renal cortices. D) 
Blood glucose and glycated hemoglobin in citrate buffer-treated wild-type (open blue circles or 
blue columns, n=10 or 4 respectively) or pCB1Rko mice (open red circles or red columns, n=10 
or 3 respectively), and streptozotocin-treated wild-type (open blue triangles or blue hatched 
columns, n= 12 or 5 respectively) or pCB1Rko mice (open red triangles or red hatched columns, 
n=15 or 3 respectively). E) BUN and albuminuria in citrate buffer-treated wild-type (blue columns, 
n=10) or pCB1Rko mice (red columns, n=10), and streptozotocin-treated wild-type (blue hatched 
columns, n=12) or pCB1Rko mice (red hatched columns, n=15). F) Podocyte numbers assessed 
by immunohistochemistry using Wilms’ Tumor 1 (WT-1) or podocalyxin staining to evaluate the 
number of nuclei and podocyte membrane integrity (scale bars 50µm). Glomerular tuft area 
quantification after PAS staining. G) Gene expression for podocin (Nphs2), nephrin (Nphs1), 
Zonula occludens (Tjp1) and desmin (Des) in citrate buffer-treated wild-type (blue columns, n=10) 
or pCB1Rko mice (red columns, n=5), and streptozotocin-treated wild-type (blue hatched 
columns, n=12) or pCB1Rko mice (red hatched columns, n=15). Columns and bars represent 
means ± SEM. Significant differences from values in citrate buffer-treated wild-type mice 
*P<0.05, **P<0.01, *** P<0.001 or streptozotocin-treated wild-type mice #P<0.05, ##P<0.01, 
### P<0.001. 
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Figure 3: Effects of Cnr1 deletion in podocytes on proximal tubular cell injury and loss of 
function. 
A) Urine output, glycosuria, urinary N-acetyl-β-D-glucosaminidase (NAG) activity, cortical gene 
expression of megalin (Lrp2) and sodium-glucose co-transporter 2 (SGLT2 Slc5a2). B) Arginase-
2 and lipocalin-2 protein expression analysis by immuno-staining (scale bars 100 μm), and fibrosis 
assessment by Picro-Sirius red staining (scale bars 100 μm) and cortical gene expression of 
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collagen 1 (Col1a), metallopeptidase inhibitor 1 (Timp1), TGF-β (Tgfb1) and fibronectin (Fn-1). 
C) Caspase 3/7 activity in renal cortices from citrate buffer-treated wild-type (blue columns, n=10) 
or pCB1Rko mice (red columns, n=10), and streptozotocin-treated wild-type (blue hatched 
columns, n=12) or pCB1Rko mice (red hatched columns, n=15). Columns and bars represent 
means ± SEM. Significant differences from values in citrate buffer-treated wild-type mice 
*P<0.05, **P<0.01, *** P<0.001 or streptozotocin-treated wild-type mice #P<0.05, ##P<0.01, 
### P<0.001. 
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Figure 4: Cnr1 deletion in podocytes reduces oxidative stress, macrophages infiltration and 
renal inflammation while improving renal microcirculation. 
A) Reactive oxygen species (ROS) quantification in renal cortices and gene expression of NADPH 
oxidase 4 (Nox4), NADPH oxidase 1 (Nox1) and neutrophil cytosolic factor 1 (p47phox). B) 
Macrophage infiltration as assessed by Iba-1 immuno-staining (scale bars: 100µm) and cortical 
gene expression of the macrophages markers CD68 (Cd68) F4/80. C) Gene expression of CCL2 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
(Ccl2), TNF-α (Tnf), IL-6 (Il6), IL-1β (Il1b) and IL-18 (Il18) in renal cortices from citrate buffer-
treated wild-type (blue columns, n=10) or pCB1Rko mice (red columns, n=10), and 
streptozotocin-treated wild-type (blue hatched columns, n=12) or pCB1Rko mice (red hatched 
columns, n=15). D) Representative illustration of renal microcirculation assessment by Laser 
speckle contrast analysis. E) Immunoreactive HIF-1α and VEGF-A protein expression and mRNA 
levels in renal cortical sections; thrombospondin-1 (Thbs1) and NADH dehydrogenase 
[ubiquinone] 1 alpha subcomplex, 4-like 2 (Ndufa4l2) gene expression is also shown. F) Pyruvate, 
lactate concentration and lactate/pyruvate ratio in renal cortices from citrate buffer-treated wild-
type (blue columns, n=10) or pCB1Rko mice (red columns, n=10), and streptozotocin-treated 
wild-type (dark hatched columns, n=12) or pCB1Rko mice (red hatched columns, n=15). Columns 
and bars represent means ± SEM. Significant differences from values in citrate buffer-treated wild-
type mice *P<0.05, **P<0.01, *** P<0.001 or streptozotocin-treated wild-type mice #P<0.05, 
##P<0.01, ### P<0.001. 
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Figure 5: Podocyte-derived factors potentiate high glucose-induced proximal tubular cell 
injury. 
A) CNR1 gene expression in human RPTC exposed to normal glucose (white), high glucose 
(black), podocyte-conditioned medium (green) or podocyte-conditioned medium 
containing 100 nM JD5037 (green with white hatch). B) LRP2, LCN2, VIM-1 and ARG2 
gene expression in RPTC exposed to normal glucose (white), high glucose (black), 
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podocyte-conditioned medium (green) or podocyte-conditioned medium with JD5037 
(green with white hatch). C) CCL2, TNF, IL18 and TGFB gene expression in RPTC 
exposed to normal glucose (white), high glucose (black), podocyte-conditioned medium 
(green) or podocyte-conditioned medium with JD5037 (green with white hatch). D) 
Schematic illustration of the proposed mechanism by CB1R-expressed podocytes mitigate 
podocyte and tubular injury. This illustration was prepared using a template on the Servier 
medical art website (http://www.servier.com/Powerpoint-image-bank). Columns and bars 
represent means ± SEM from 2 independent experiments and 6 replicates per group. 
Significant differences from values in RPTC in normal glucose, *P<0.05, **P<0.01, *** 
P<0.001. Significance of the effect of JD5037 in RPTC in high glucose, #P<0.05, 
##P<0.01, ### P<0.001. Significance of the effect of conditioned medium in RPTC in high 
glucose &P<0.05, &&P<0.01, &&& P<0.001. 
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